

INFLUENZA VACCINES FOR THE WORLD

2-4 April 2019, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR IVW 2019

Influenza Vaccines for the World – IVW 2019 is the seventh international conference and exhibition in this important series of influenza vaccine meetings. The IVW conference series focuses on 'Influenza Vaccination Issues'.

The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants/delivery/vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines/technologies and their availability/delivery/implementation worldwide.

The IVW 2019 Scientific Advisory Panel invites the influenza community worldwide to submit abstracts for consideration for inclusion in the IVW 2019 oral & poster scientific programmes.

SCIENTIFIC ADVISORY PANEL

Othmar Engelhardt (NIBSC/HPA, Potters Bar, UK)

Rosalind Hollingsworth (Sanofi Pasteur, Swiftwater, Pennsylvania, USA)

John Oxford (Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

Albert Osterhaus (University of Veterinary Medicine Hannover, Hannover, Germany)

Ted Ross (University of Georgia, Athens, Georgia, USA)

Yoshihiro Kawaoka (University of Wisconsin, Madison, Wisconsin, USA)

Helen Bright (MedImmune, Liverpool, UK)

Jonathan Van-Tam (Department of Health and Social Care, London, UK)

Rob Lambkin-Williams (hVIVO Ltd., London, UK)

Dirk Poelaert (GSK Vaccines, Wavre, Belgium)

Ronald Kompier (FluConsult, Noordwijk, The Netherlands)

Erin Grace Sparrow (WHO, Geneva, Switzerland)

Manon Cox (NextWaveBio, East Haven, Connecticut, USA)

Emanuele Montomoli (VisMederi Srl, Siena, Italy)

Yotam Levin (NanoPass Technologies Ltd, Rehovot, Israel)

Manmohan Singh (Takeda Vaccines, Morrisville, North Carolina, USA)

Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)

Edward Remarque (BPRC, Rijswijk, The Netherlands)

Myra Widjoatmodjo (Janssen Vaccines, Leiden, The Netherlands)

Sean Tucker (VAXART Inc, South San Francisco, California, USA)

Nathalie Charland (Medicago, Quebec, Canada)

Kathy L. Rowlen (InDevR Inc, Boulder, Colorado, USA)

Shan Lu (University of Massachusetts Medical School, Worcester, Massachusetts, USA)

Carrie Pierce (Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA)

Jon Bundy (Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA)

Tamar Ben-Yedidia (BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel)

Yuri Vasiliev (Research Institute of Ultrapure Biologicals, St. Petersburg, Russian Federation)

Bram Palache (FluPal Consultancy BV, Amstelveen, The Netherlands)

Baozhong Wang (Georgia State University, Atlanta, Georgia, USA)

Otfried Kistner (Senior Consultant, Vienna, Austria)

CONFERENCE SCOPE



IVW 2019 will address the following important topics:

Surveillance Issues / Burden of Disease · Immunological Issues · Social / Political / Financial Issues Surrounding Influenza Vaccination

Novel Developments · Production / Formulation Issues / Manufacturing Issues · Vaccine Usage / Targeting Strategies

Influenza Vaccines / Adjuvants – Improvement Issues · Pandemic Preparedness Issues / Licensing Issues

The scientific programme will include keynote lectures, contributed papers, workshops, panel discussions, satellite symposia and poster presentations emphasising all aspects of 'Influenza Vaccines' and their usage and effectiveness. Potential authors are invited to submit abstracts on any of the above topics for consideration for inclusion within the conference program.



**SESSION 1:
OPENING PLENARY SESSION**

Moderator: John Oxford
(Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

OPENING KEYNOTE:

'Replication and pathogenesis of influenza viruses'

Paul Digard
(The Roslin Institute, University of Edinburgh, Midlothian, Scotland, UK)

**SESSION 2:
INFLUENZA VACCINES
& PUBLIC HEALTH CHALLENGES**

Moderator: John Oxford
(Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

KEYNOTE:

'WHO strategy for influenza 2019-2030: The "priorities" and most urgent needs to improve seasonal influenza control and pandemic preparedness'

Ann Moen
(WHO, Geneva, Switzerland)

KEYNOTE:

'Influenza vaccines: From science into public health policy'

Jon Van Tam
(UK Department of Health, London, UK)

'Influenza: Why vaccine uptake matters'

Bram Palache
(IFPMA/FluPal Consultancy BV, Amstelveen, The Netherlands)

Coffee Break & Poster Set-Up

**SESSION 3:
PANDEMIC VACCINES & PREPAREDNESS**

Moderator: Jon Van Tam
(UK Department of Health, London, UK)

KEYNOTE:

'The military Final Push: An international attempt to stop a pandemic at source by vaccination'

John Oxford
(Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

'Pandemics, vaccine availability and use'

Lone Simonsen
(The George Washington University, Washington DC, USA)

'Influenza Pandemics: Are we ready for the next one?'

Bram Palache
(IFPMA/FluPal Consultancy BV, Amstelveen, The Netherlands)

Lunch Break & Posters

**SESSION 4:
INFLUENZA VACCINES DEVELOPMENTS – I**

Moderator: To be confirmed

KEYNOTE:

'The young and the old as a challenge for influenza vaccine development'

Timo Vesikari
(University of Tampere, Tampere, Finland)

KEYNOTE:

'Egg-based vs. cell culture-based human influenza vaccines'

John McCauley
(Francis Crick Institute, London, UK)

'Getting closer to the market: M-001 universal flu vaccine pivotal phase 3 trial'

Tamar Ben-Yedidia
(BiondVax Pharmaceuticals Ltd., Ness Ziona, Israel)

Tea Break & Posters

**SESSION 5:
INFLUENZA VACCINES DEVELOPMENTS – II
ANTIGEN DESIGN & CHARACTERIZATION**

Moderator: To be confirmed

KEYNOTE:

'Recent progress in novel, cross-reactive and universal influenza vaccines'

Sean Tucker
(VAXART Inc, South San Francisco, California, USA)

'Next-generation broadly reactive influenza vaccines'

James D. Allen
(University of Georgia, Athens, Georgia, USA)

'Development of a T cell-based universal influenza vaccine'

Chris Ellis
(Vaccitech Ltd., Oxford, UK)

'Immune engineering: A strategy to couple B cell and T cell immunity for improved pandemic and universal influenza vaccines'

Lenny Moise
(EpiVax Inc., Providence, Rhode Island, USA)

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 8th March 2019. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 8th March 2019.

**SESSION 6:
INFLUENZA VACCINES DEVELOPMENTS – III
ANTIGEN DESIGN & CHARACTERIZATION**

Moderator: Ted Ross

(University of Georgia, Athens, Georgia, USA)

'Re-examining the current polyvalent design of flu vaccines'

Shan Lu

(University of Massachusetts, Worcester, Massachusetts, USA)

'The epitope dilution phenomenon: A way to address variable antigens'

Ed Remarque

(BPRC, Rijswijk, The Netherlands)

'VaxArray platform for rapid assessment of hemagglutinin and neuraminidase in influenza vaccines'

Kathy L. Rowlen

(InDevR Inc. Boulder, Colorado, USA)

Coffee Break & Posters

**SESSION 7:
INFLUENZA VACCINES DEVELOPMENTS – IV
MECHANISMS OF ACTION & CORRELATES
OF PROTECTION**

Moderator: Shan Lu

(University of Massachusetts, Worcester, Massachusetts, USA)

'Impact of age and pre-existing immunity on influenza-specific B cells and induction of enhance antibody breadth following vaccination in humans'

Ted M. Ross

(University of Georgia, Athens, Georgia, USA)

'New approaches to the development of effective influenza vaccines'

Tokiko Watanabe¹ and Yoshihiro Kawaoka²

(¹ University of Tokyo, Tokyo, Japan; ² University of Wisconsin, Madison, Wisconsin, USA)

'Influenza virus infection as well as immunization induces high titre cross-reactive haemagglutinin-specific antibody-dependent phagocytosis (ADP) and monocyte infection-enhancing responses in macaques'

Ed Remarque

(BPRC, Rijswijk, The Netherlands)

'Novel influenza vaccines: Impact on serological analysis and immune correlates'

Otfried Kistner

(Senior Consultant, Vienna, Austria)

Lunch Break & Posters

**SESSION 8:
INFLUENZA VACCINES DEVELOPMENTS – V
ROUTES OF ADMINISTRATION & ADJUVANTS**

Moderator: Ed Remarque

(BPRC, Rijswijk, The Netherlands)

'Micro array patch: Phase I study with influenza vaccine'

Julian Hickling

(Vaxaas, Woolloongabba, Brisbane, Australia)

'Improved influenza vaccination through infection mimicry using silk microneedles'

Kathryn Kosuda

(Vaxess Technologies Inc., Cambridge, Massachusetts, USA)

'Microneedle skin vaccination of flagellin-M2e fusion protein and inactivated influenza vaccines confers cross protection'

Baozhong Wang

(Georgia State University, Atlanta, Georgia, USA)

'Intradermal adjuvants: The future of vaccine enhancement. Clinical trials and insights'

Yotam Levin

(NanoPass Technologies Ltd, Rehovot, Israel)

'IgA is critical for protection against influenza following mucosal delivery'

Nikita Kolhatkar

(VAXART Inc, South San Francisco, California, USA)

Tea Break & Posters

**SESSION 9:
CLINICAL DEVELOPMENT OF NEXT-GENERATION
INFLUENZA VACCINES**

Moderator: Otfried Kistner

(Senior Consultant, Vienna, Austria)

'Novel live M2SR vaccine elicits broadly cross-reactive immune responses in human subjects'

Pamuk Bilsel

(FluGen Inc., Madison, Wisconsin, USA)

'Update on the clinical development of a plant-derived quadrivalent virus-like particles influenza vaccine'

Nathalie Landry

(Medicago Inc., Quebec City, Quebec, Canada)

'Flumist / Fluenz vaccine effectiveness and its return to US market'

Helen Bright

(MedImmune UK Ltd, Liverpool, UK)

'A combined universal/seasonal flu vaccine: A protein nanoparticle vaccine that allows rapid manufacturing'

Peter Burkhard

(Alpha-O Peptides AG, Riehen, Switzerland)

'Influenza virus-based vector platform for respiratory mucosal vaccination'

Andrey Vasin, Marina Stukova, Andrey Egorov, Maria Sergeeva, Anna-Polina

Shurygina, Kirill Vasilev, Janna Buzitskaya and Katya Romanovskaya-Romanko

(Research Institute of Influenza, St. Petersburg, Russia)

**SESSION 10:
SUBMITTED PRESENTATIONS – I**

Moderator: Manon Cox

(NextWaveBio, East Haven, Connecticut, USA)

‘Safety and immunogenicity of the Polyoxidonium®-adjuvanted subunit influenza vaccine. A systematic review and meta-analysis of clinical trials’

R. Kompier and W.E. Beyer

(FluConsult, Noordwijk, The Netherlands)

‘Polyoxidonium’-based low-dose “Grippol® Quadrivalent” vaccine effectively stimulates dendritic cells maturation and immune response’

V.Yu. Talayev¹, A.V. Matveichev², N.V. Volkova², I.E. Zaichenko¹, M.V. Talaeva¹,

V.F. Ostrov², O.N. Babaykina¹, E.V. Voronina¹ and O.I. Orekhova²

(¹ Federal Budget Institution of Science, Nizhny Novgorod Scientific and Research

Institute of Epidemiology and Microbiology I.N. Blokhina, Federal Service on

Surveillance for Consumer Rights Protection and Human Welfare

(Rospotrebnadzor), Moscow, Russia; ² NPO Petrovax Pharm, LLC, Podolsk,

Moscow Region, Russia)

‘DNA vaccination with HLAII-targeted hemagglutinin to quench an emerging pandemic threat’

Gunnveig Grødeland¹, Tor Kristian Andersen¹, Agnete B. Fredriksen²

and Bjarne Bogen¹

(¹ K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical

Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; ²

Vaccibody AS, Oslo, Norway)

‘OVX836, a multimerized nucleoprotein-based vaccine candidate protects mice against lethal challenge with multiple strains of influenza A viruses’

Judith Del Campo¹, Andrés Pizzorno², Marion Chevandier¹, Marjorie Haller¹, Julien

Bouley¹, Thomas Julien², Guy Boivin³, Marie-Eve Hamelin³, Florence Nicolas¹,

Alexandre Le Vert¹, Manuel Rosa-Calatrava² and Fergal Hill¹

(¹ Osivax, Lyon, France; ² Virologie et Pathologie Humaine – VirPath Team, Centre

International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS

UMR5308, ENS Lyon, Université Claude Bernard Lyon, Université de Lyon, Lyon,

France; ³ Centre de Recherche en Infectiologie of the Centre Hospitalier

Universitaire de Québec and Université Laval, Québec, Canada)

Coffee Break & Posters

**SESSION 11:
SUBMITTED PRESENTATIONS – II**

Moderator: To be confirmed

‘Title to be confirmed’

Ruben Maeso

(Seqirus, Liverpool, Merseyside, UK)

Lunch Break & Posters Breakdown

**SESSION 12:
LATEBREAKER ORAL PRESENTATIONS**

Moderator: To be confirmed

Authors interested in submitting latebreaker oral abstracts should submit their abstracts direct to John Herriot at Meetings Management (IVW 2019 Organizers).

Please email your latebreaker abstracts to jherriot@meetingsmgmt.u-net.com

Closing date for latebreaker submissions is Friday 8th March 2019.

Tea Break

**SESSION 13:
CLOSING PLENARY SESSION**

Moderator: John Oxford

(Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

‘Are there good reasons to recommend paediatric influenza vaccination for all children in Europe?’

Dirk Poelart

(GSK Vaccines, Wavre, Belgium)

‘Influenza vaccines from Russia: A historical overview and recent developments’

Yuri Vasiliev

(Research Institute of Ultrapure Biologicals, St. Petersburg, Russian Federation)

Closing Remarks & Departure

* This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 8th March 2019. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 8th March 2019.

REGISTRATION

Delegates should register for IVW 2019 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the IVW 2019 Conference Manager – Caroline Sumner at Meetings Management. The IVW 2019 Conference Registration Desk will be open from 7.30am on Tuesday 2nd April 2019.

Delegates can also register securely on-line at:

http://www.meetingsmanagement.com/ivw_2019

VENUE & ACCOMMODATION

The venue for IVW 2019 is The Royal College of Physicians of Edinburgh in Edinburgh, United Kingdom.

THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH

9 Queen Street, Edinburgh EH2 1JQ, United Kingdom

Tel: +44 (0)131 225 7324

Fax: +44 (0)131 220 3939

Web: www.rcpe.ac.uk

There are numerous hotels in Edinburgh to suit most budgets. For information and details on local accommodation in Edinburgh convenient for the college venue, please visit the IVW 2019 website and view the accommodation section for details:

http://www.meetingsmanagement.com/ivw_2019

Please note that the IVW 2019 conference organizers will not be recommending any specific hotels in Edinburgh. April is a busy time in Edinburgh and it is recommended that IVW 2019 delegates book their accommodation without delay.

PUBLICATION

A USB storage device containing the final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £3000.00 (£2500.00+20% VAT). If you do not wish to attend the conference sessions, you can reserve a table for £6000.00 (£5000.00+20% VAT) (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Table Top Exhibition facilities at IVW 2019 should be directed to John Herriot at Meetings Management (jherriot@meetingsmgmt.u-net.com).

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the IVW 2019 delegate pack is priced at £930.00 (£775.00+20% VAT). Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at IVW 2019 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: Literature for distribution to IVW 2019 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at IVW 2019. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The IVW 2019 Scientific Advisory Panel and the IVW 2019 Conference Organizers reserve the right to alter any part of the published conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization's library up to date. The cost of providing this non-attendee package is £714.00 (£595.00+20% VAT) (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner, IVW 2019 Conference Manager:

IVW 2019 Conference Secretariat, Meetings Management

Forge Cottage, Bowlhead Green, Godalming, Surrey GU8 6NW, United Kingdom.

Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

E-mail: csumner@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 8th March 2019. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 8th March 2019.

Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname First Name Title

Organization Address

..... Postcode

Country Telephone Fax

E-mail (plain type or print):

If you are an EC business please state your VAT registration number:

Disabled (please state any special needs): Special diet (please state requirements):

REGISTRATION FEES

Speaker/Delegate Registration Fees: (NOTE THAT FEES ARE IN UK £ STERLING) DELEGATE REGISTRATION FORMS NOT DULY & FULLY COMPLETED WILL NOT BE VALID
 (Please tick appropriate section) Amount Due (£ Sterling)

Speaker Registration (submitted oral/poster papers) £954.00 (£795.00+20% VAT) £.....
 (Payment must be received before Friday 25th January 2019)

Reduced Early Bird Registration £1078.80 (£899.00+20% VAT) £.....
 (Payment must be received before Friday 25th January 2019)

Full Registration £1198.80 (£999.00+20% VAT) £.....
 (Payment received after Friday 25th January 2019)

Student Registration Price on application £.....

Table Top Exhibits/Delegate Pack Inserts

Table Top Exhibit (I am registered to attend) £3000.00 (£2500.00+20% VAT) £.....

Table Top Exhibit (I am NOT registered to attend) £6000.00 (£5000.00+20% VAT) £.....

PLEASE NOTE: The above payments for Table Top Exhibits are for 1 company representative only. If you require additional representatives please contact the Conference Manager for a price.

Delegate Pack Insert £930.00 (£775.00+20% VAT) £.....

For those Unable to Attend

Set(s) of IVW 2019 materials @ £714.00 (per set) (£595.00+20% VAT) £.....

Total Amount Payable £.....

Registration fees include admission to all conference sessions, morning and afternoon refreshments and lunches on the 2nd, 3rd and 4th April 2019.

PAYMENT

I enclose a cheque for £..... made payable to **Meetings Management**. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote **IVW 2019** on the reverse of the cheque.)

I have made a payment by bank transfer (quoting **IVW 2019** on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK:

UK Pounds Sterling Account: Meetings Management 0040614335 US Dollar Account: Meetings Management 53209211
 IBAN: GB11BUKB20353540614335 SWIFTBIC: BUKGBG22 IBAN: GB86BUKB20353553209211 SWIFTBIC: BUKGBG22

Euro Account: Meetings Management 59179600
 IBAN: GB03BUKB20353559179600 SWIFTBIC: BUKGBG22

All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. **Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 1ST FEBRUARY 2019. LATE PAYMENT AFTER FRIDAY 1ST FEBRUARY 2019 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).**

I would like to pay £..... by credit card (VISA/MasterCard/American Express only accepted).

Card no. 3 Digit Security Code (AMEX: 4 Digits)

Expiry Date Registered Card Address

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 1st February 2019 will be refunded in full less an administrative charge of £275 per person. Refunds will not be possible if a cancellation is received after Friday 1st February 2019. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees. VAT No. GB-591 6176 18

Signature Date

PLEASE RETURN THIS FORM TO:

IVW 2019 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT
 Forge Cottage, Bowlhead Green, Godalming, Surrey GU8 6NW, United Kingdom
 Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: csumner@meetingsmgmt.u-net.com